Scopus Eşleşmesi Bulundu
7
Atıf
23
Cilt
740-748
Sayfa
Özet
Background: Endometrial cancer is one of the most common types of cancer. For this rea-son, various studies have been carried out on its treatment and the effects of natural products on this disease. Objectives: This study aimed to examine the growth inhibitory effects of Eryngium kotschyi Boiss. ethyl acetate [EKE] and butanol [EKB] obtained from the main methanol [EKM] extract from the aerial parts on human endometrium carcinoma [RL95-2] cells and their synergistic effect with cisplatin or doxoru-bicin. Methods: RL95-2 cells were treated with E. kotschyi extracts either alone or in combination with cispla-tin or doxorubicin. The effects on cell growth were determined using the MTT assay and real-time cell analysis xCELLigence. Results: The extracts demonstrated growth inhibitory activity, with a certain degree of selectivity against the RL95-2 cell line. Synergistic effects of EKE/cisplatin or doxorubicin at different concentration levels were demonstrated in RL95-2 cells. In some instances, the EKE/doxorubicin combinations resulted in antagonistic effects. The reduction level of cell viability was different and specific to each combination for the RL95-2 cell line. Conclusion: The growth inhibitory activity of cisplatin or doxorubicin, as a single agent, may be modi-fied by combinations of the extracts and be synergistically enhanced in some cases. A significant synergistic effect of EKE on the RL95-2 cell line with cisplatin and doxorubicin was observed. This cytotoxic effect can be investigated in terms of molecular mechanisms. This study is the first of its kind in the literature. The mechanisms involved in this interaction between chemotherapeutic drugs and plant extracts remain unclear and should be further evaluated.
Web of Science Eşleşmesi Bulundu
6
WoS Atıf
23
Cilt
Article
Belge Türü
Kaynak: CURRENT PHARMACEUTICAL BIOTECHNOLOGY
· s. 740-748
Anahtar Kelimeler (WoS)
Havuzumuzdaki Atıflar 0
Bu makaleye, sistemimizdeki Scopus veritabanında bulunan 0 makale atıf yapmıştır. Scopus genel atıf sayısı: 7.
Bu makaleye, kendi Scopus havuzumuzdaki başka bir makaleden atıf kaydı bulunmuyor.
Scimago Dergi Bilgisi
Otomatik ISSN Eşleştirmesi
2022 yılı verileri
Current Pharmaceutical Biotechnology
Q2
SJR Quartile
0,459
SJR Skoru
101
H-Index
Kategoriler: Pharmaceutical Science (Q2) · Biotechnology (Q3)
Alanlar: Biochemistry, Genetics and Molecular Biology · Pharmacology, Toxicology and Pharmaceutics
Ülke: United Arab Emirates
· Bentham Science Publishers
Bu bilgiler makale yılına göre Scimago veritabanından ISSN eşleştirmesiyle otomatik getirilmektedir.
Dergi sıralama verileri Scimago'nun ilgili yılı baz alınmaktadır.
Anahtar Kelimeler
WoS |
Bir kelimeye tıklayıp ilgili kaynaktaki yayınları görün.
Makale Bilgileri
Dergi
CURRENT PHARMACEUTICAL BIOTECHNOLOGY
ISSN
1389-2010
Yıl
2022
/ 4. ay
Cilt / Sayı
23
Sayfalar
740 – 748
Makale Türü
Özgün Makale
Hakemlik
Hakemli
Endeks
SCI-Expanded
Teşvik Puanı
2,03
· YÖKSİS Akademik Teşvik
Yayın Dili
İngilizce
Kapsam
Uluslararası
Toplam Yazar
4 kişi
Erişim Türü
Basılı+Elektronik
Alan
Fen Bilimleri ve Matematik Temel Alanı
Biyoloji
YÖKSİS Yazar Kaydı
Yazar Adı
KARABOĞA ARSLAN AYŞE KÜBRA, PASHAYEVA LEYLA, ESEN MERVE AYŞE, TUGAY OSMAN
YÖKSİS ID
6913840